Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H15FN2O2S |
Molecular Weight | 318.366 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O
InChI
InChIKey=MMSNEKOTSJRTRI-LLVKDONJSA-N
InChI=1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)/t11-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/7490726Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/27883201 | https://www.ncbi.nlm.nih.gov/pubmed/25752438
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7490726
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/27883201 | https://www.ncbi.nlm.nih.gov/pubmed/25752438
Atreleuton is a potent, orally administered, selective 5-Lipoxygenase inhibitor. Atreleuton had been in phase III clinical trials for the treatment of asthma and phase II clinical trials for the treatment of acute coronary syndrome and atherosclerosis. However, this research has been discontinued.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL215 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7490726 |
23.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9923573 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. | 1995 Nov 24 |
|
ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. | 1997 Mar |
|
The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. | 1997 Mar |
|
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. | 2011 Dec 8 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10099073
200 mg once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7490726
Inhibition of LTB4 formation in calcium ionophore-stimulated purified human neutrophils from four donors gave a mean IC50 of 23 nM. In the more complex medium of human whole blood, Atreleuton was a selective inhibitor of calcium ionophorestimulated LTB4 formation with an IC50 of 150 nM (95%, cl 100-200). In the same assay an IC50 of 11 uM (95%, cl 8-12) was measured for 12-HETE, 50% inhibition of 15-HETE was observed at the highest dose tested of 100 uM, and an IC50 of 50 uM (95%, cl 37-78) was found for the formation of TXB2.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1322
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7667
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
SUB05604MIG
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
154355-76-7
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
DB12758
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
U301T88E1M
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
3086671
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
DTXSID10165598
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
100000086656
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
C64176
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
JJ-03
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL59356
Created by
admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY